USS Investment Management Ltd Has $195.23 Million Stock Holdings in Johnson & Johnson $JNJ

Key Points

• USS Investment Management Ltd reduced its stake in Johnson & Johnson by 14.6% in the first quarter, now holding 1,176,886 shares valued at approximately $195.2 million.
• Several large investors, including UniSuper Management Pty Ltd and Richwood Investment Advisors LLC, made adjustments to their Johnson & Johnson holdings during the same period, demonstrating ongoing institutional interest in the stock.
• Johnson & Johnson recently declared a quarterly dividend of $1.30 per share, reflecting an annualized yield of 2.9% and a payout ratio of 55.61%.

USS Investment Management Ltd cut its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 14.6% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,176,886 shares of the company's stock after selling 201,500 shares during the quarter. Johnson & Johnson accounts for 1.5% of USS Investment Management Ltd's portfolio, making the stock its 18th biggest holding. USS Investment Management Ltd's holdings in Johnson & Johnson were worth $195,228,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of the business. Vanguard Group Inc. boosted its position in Johnson & Johnson by 0.5% during the first quarter. Vanguard Group Inc. now owns 233,962,679 shares of the company's stock worth $38,800,371,000 after purchasing an additional 1,170,120 shares in the last quarter. Northern Trust Corp lifted its position in shares of Johnson & Johnson by 0.4% in the first quarter. Northern Trust Corp now owns 30,943,820 shares of the company's stock valued at $5,131,723,000 after acquiring an additional 130,645 shares in the last quarter. Bank of New York Mellon Corp increased its stake in Johnson & Johnson by 26.4% in the first quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company's stock valued at $3,844,580,000 after purchasing an additional 4,842,582 shares during the last quarter. Charles Schwab Investment Management Inc. increased its stake in Johnson & Johnson by 3.9% in the first quarter. Charles Schwab Investment Management Inc. now owns 18,899,263 shares of the company's stock valued at $3,133,602,000 after purchasing an additional 712,181 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA increased its stake in Johnson & Johnson by 2.5% in the first quarter. Massachusetts Financial Services Co. MA now owns 18,282,410 shares of the company's stock valued at $3,031,955,000 after purchasing an additional 448,666 shares during the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on JNJ shares. Barclays upped their price target on Johnson & Johnson from $165.00 to $176.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 17th. Leerink Partners lowered Johnson & Johnson from an "outperform" rating to a "market perform" rating and lowered their target price for the company from $169.00 to $153.00 in a research note on Tuesday, May 13th. Erste Group Bank raised Johnson & Johnson from a "hold" rating to a "buy" rating in a report on Wednesday, July 23rd. UBS Group increased their target price on Johnson & Johnson from $180.00 to $190.00 and gave the stock a "buy" rating in a report on Thursday, July 17th. Finally, Guggenheim reaffirmed a "neutral" rating and set a $167.00 target price (up previously from $164.00) on shares of Johnson & Johnson in a report on Thursday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat.com, Johnson & Johnson has a consensus rating of "Moderate Buy" and a consensus target price of $176.29.

Johnson & Johnson Price Performance

Shares of NYSE JNJ traded down $0.13 during mid-day trading on Monday, reaching $178.30. The company had a trading volume of 8,325,117 shares, compared to its average volume of 7,659,331. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The stock has a market cap of $429.40 billion, a PE ratio of 19.07, a P/E/G ratio of 2.27 and a beta of 0.40. The company has a 50-day moving average price of $169.09 and a two-hundred day moving average price of $160.90. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $181.16.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.68 by $0.09. The business had revenue of $23.74 billion for the quarter, compared to analysts' expectations of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The company's quarterly revenue was up 5.8% on a year-over-year basis. During the same period in the previous year, the firm posted $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, equities analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be given a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 2.9%. The ex-dividend date of this dividend is Tuesday, August 26th. Johnson & Johnson's dividend payout ratio (DPR) is 55.61%.

Insider Activity at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the firm's stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares of the company's stock, valued at $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.